Anthropic Launches Claude Science and Starts Its Own Drug Program
The AI lab debuted a drug-discovery workbench for pharma and, in the same announcement, said it will begin developing treatments of its own, starting with neglected diseases.
At an event in San Francisco on 30 June, Anthropic launched Claude Science, an AI workbench aimed at pharmaceutical researchers that tries to pull the fragmented tools of drug discovery into one place. In the same announcement, the company said it will start an internal drug-discovery program of its own.
The in-house effort will target ‘neglected’ diseases — conditions that traditional biopharma companies treat as unattractive because the market is too small to justify the cost. Anthropic’s life-sciences lead framed the move as a way to build better tools by developing drugs alongside the customers it is courting, citing the value of tight feedback loops and being ‘in the trenches.’
The company, a public-benefit corporation, said it can choose programs on patient benefit, including work the commercial market overlooks. It did not say what it would do with any promising candidate it finds; conventional developers would move such compounds into clinical trials.
The step puts Anthropic among the large technology firms that have pushed into healthcare from different directions — Alphabet, Apple and Amazon among them — but here the reasoning model itself moves down the stack, from supplier of software to developer of the drug.
The longer view
One headline rarely tells the story. See how today’s news fits the bigger shifts on AI Trends, or learn to read your own data on How it works.